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The human drug metabolizing cytochrome P450 (CYP) 1A2, is one of the major P450 isoforms 
contributing by about 5–20% to the hepatic P450 pool and catalyzing oxidative biotransformation 
of up to 10% of clinically relevant drugs including clozapine and caffeine. CYP1A2 activity is 
interindividually highly variable and although twin studies have suggested a high heritability, 
underlying genetic factors are still unknown. Here we adopted a pathway-oriented approach 
using a large human liver bank (n = 150) to elucidate whether variants in candidate genes 
of constitutive, ligand-inducible, and pathophysiological inhibitory regulatory pathways may 
explain different hepatic CYP1A2 phenotypes. Samples were phenotyped for phenacetin 
O-deethylase activity, and the expression of CYP1A2 protein and mRNA was determined. 
CYP1A2 expression and function was increased in smokers and decreased in patients with 
inflammation and cholestasis. Of 169 SNPs in 17 candidate genes including the CYP1A locus, 
136 non-redundant SNPs with minor allele frequency >5% were analyzed by univariate and 
multivariate methods. A total of 13 strong significant associations were identified, of which 10 
SNPs in the ARNT, AhRR, HNF1α, IL1β, SRC-1, and VDR genes showed consistent changes 
for at least two phenotypes by univariate analysis. Multivariate linear modeling indicated that 
the polymorphisms and non-genetic factors together explained 42, 38, and 33% of CYP1A2 
variation at activity, protein and mRNA levels, respectively. In conclusion, we identified novel 
trans-associations between regulatory genes and hepatic CYP1A2 function and expression, but 
additional genetic factors must be assumed to explain the full extent of CYP1A2 heritability.
Keywords: candidate gene, cytochrome P450, CYP1A2, multivariate analysis, non-genetic factors, pharmacogenetics, 
pharmacogenomics, SNP
  antidepressant duloxetine (Lobo et al., 2008),   theophylline (Ha 
et al., 1995), and caffeine (Butler et al., 1989, which is commonly 
used for CYP1A2 in vivo phenotyping (e.g., Fuhr et al., 2007). 
CYP1A2 was also shown to activate procarcinogens, such as aro-
matic heterocyclic amines, and polycyclic aromatic hydrocarbons 
(Boobis et al., 1994; Eaton et al., 1995; Kim and Guengerich, 
2005).
Like other drug metabolizing enzymes, CYP1A2 activity is highly 
variable and a number of environmental, non-genetic and genetic 
as well as epigenetic factors have been shown to play a role (Gunes 
and Dahl, 2008; Ghotbi et al., 2009).
Drug–drug interactions are one prominent source of clini-
cally relevant variability and several high-affinity and irreversible 
inhibitors of this enzyme have been identified, including, for 
example, the potent irreversible inhibitor fluvoxamine (Gunes 
and Dahl, 2008; Zhou et al., 2009). Furthermore, all three CYP1 
genes are coordinately regulated by the Ah-receptor pathway, 
which leads to induced levels in smokers (Schweikl et al., 1993; 
Bock  et  al.,  1994;  Sesardic  et  al.,  1998;  Ghotbi  et  al.,  2007; 
Pelkonen et al., 2008) and after exposure to other   xenobiotics 
(Pelkonen et al., 2008).
There is also evidence from several studies that CYP1A2 activity 
is higher in men than in women (Relling et al., 1992; Rasmussen 
and Brøsen, 1996; Scandlyn et al., 2008).
IntroductIon
The cytochrome P450, CYP1A2, is one of three P450 isoforms 
of the CYP1 family expressed in humans, the other isoforms 
being CYP1A1 and CYP1B1. It is predominantly expressed in 
liver and at lower levels in intestine, pancreas, lung, and brain 
(Gunes and Dahl, 2008; Zhou et al., 2009). In the liver, CYP1A2 
contributes about 5–20% to the total microsomal P450 pool, thus 
representing one of the major drug metabolizing enzymes and 
contributing significantly to the oxidative metabolism of 10–15% 
of clinically relevant drugs. Among these are the antipsychotic 
clozapine (Bertilsson et al., 1994; Eiermann et al., 1997), the 
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included genes that have been previously implicated in CYP1A2 
constitutive, inducible, and pathophysiological transcriptional 
regulation,  such  as  liver-enriched  transcription  factors  and 
co-regulators, members of the AhR pathway, and mediators of 
inflammation and immune response, as summarized in Figure 1. 
In addition, we included several nuclear receptors that function 
as xenobiotic sensors of other inducible P450s, although direct 
interaction with CYP1A2 has not been demonstrated. In addition 
we also re-analyzed numerous SNPs within the CYP1A2 gene 
that have been previously investigated as determinants of phar-
macokinetics or that have other evidence for functional impact. 
To investigate the possible impact of these genetic variants, we 
carried out univariate and multivariate association analyses in 
a large human liver bank phenotyped for CYP1A2 mRNA and 
protein expression, and enzyme activity. The clinical documenta-
tion of the samples furthermore allowed us to include a number 
of environmental and other non-genetic factors. The results sup-
port the view that some polymorphic genes in transcriptional 
regulatory pathways contribute to hepatic CYP1A2 phenotype, 
although non-genetic factors appear to be almost as important 
as genetic ones.
MaterIals and Methods
PatIents and lIver saMPles
Liver tissue and corresponding blood samples for genomic DNA 
extraction were previously collected from patients undergo-
ing liver surgery at the Department of General, Visceral, and 
Transplantation  Surgery  (A.K.Nuessler,  P.Neuhaus,  Campus 
Virchow,  University  Medical  Center  Charité,  Humboldt 
University Berlin, Germany). The study was approved by the eth-
ics committees of the medical faculties of the Charité, Humboldt 
University, and of the University of Tuebingen and conducted in 
accordance with the Declaration of Helsinki. Written informed 
consent was obtained from each patient. All tissue samples had 
been examined by a pathologist and only histologically normal 
liver tissue was collected and stored at −80°C. For each patient, 
detailed information was available regarding age, sex, smoking 
status,  alcohol  consumption,  pre-surgery  medication  (P450 
inducers as assigned in Table 1), indication for liver resection, 
and pre-surgery liver serum parameters (Table 1). Samples from 
patients with hepatitis, cirrhosis, or chronic alcohol abuse were 
excluded. A total of 150 liver samples from which high qual-
ity RNA and complete documentation could be obtained were 
finally included.
High quality total RNA was isolated from liver tissue using 
Trizol/QiagenRNeasy protocol as described previously (Gomes 
et al., 2009). Synthesis of cDNA was performed with 1 μg RNA 
using the TaqMan Reverse Transcription Kit (Applied Biosystems, 
Darmstadt, Germany) according to the supplier’s instructions. 
Expression  of  CYP1A2  mRNA  in  liver  tissue  was  performed 
using specific primers and a TaqMan-probe as described in Feidt 
et al. (2010) with a TaqMan 7500 system (Applied Biosystems, 
Darmstadt,  Germany).  A  standard  curve  was  obtained  using 
CYP1A2 cDNA-containing linearized plasmid DNA (a friendly 
gift from J. Buters; Munich, Germany). Raw data were normal-
ized to RPLP0 (60S large ribosomal protein P0) expression which 
was  determined  in  the  same  samples  using  the  endogenous 
Additional variability in CYP1A2 expression is observed   during 
inflammation (Vrzal et al., 2004) and several cytokines down-regu-
late expression in primary human hepatocytes (Abdel-Razzak et al., 
1993) or repress inducibility (Muntané-Relat et al., 1995).
Despite  these  pronounced  environmental,  sex,  and  disease-
  related factors, there is strong evidence for a significant contribu-
tion of genetic factors to interindividual variability in CYP1A2 
activity. By measuring the caffeine metabolic ratio as a CYP1A2 
activity marker in a large cohort (n = 378) of mono- and dizygotic 
twins selected to exclude the influence of smoking, oral contracep-
tives, and gender, Brøsen and colleagues found a strong overall 
heritability of 0.725 (Rasmussen et al., 2002).
To  date,  16  defined  alleles  and  additional  haplotype  vari-
ants,  comprising  more  than  30  SNPs  have  been  identified  in 
coding and non-coding regions of the CYP1A2 gene (CYPallele 
nomenclature website at http://www.cypalleles.ki.se/; inspected 
August 6, 2010).
The amino acid variants, some of which were shown to be 
functionally relevant (Chevalier et al., 2001; Murayama et al., 
2004; Zhou et al., 2004) are nevertheless of limited clinical use 
due to their rare occurrence. Among the few SNPs currently con-
sidered to be of potential predictive value, are the 5′-upstream 
variant 3860G > A (CYP1A2*1C) and the intron 1 polymorphism 
−163C > A (CYP1A2*1F) located downstream of the untranslated 
first exon. However, attempts to establish phenotype-genotype rela-
tionships were overall disappointing and a recent study concluded 
that no SNP or haplotype in the CYP1A2 gene has a clear predictive 
value (Jiang et al., 2006). Thus, although some of these variants 
have been associated with altered drug clearance and response, or 
with disease susceptibility (Gunes and Dahl, 2008; Zanger et al., 
2008), it appears that the basis for inheritable CYP1A2-dependent 
phenotypes has not been satisfactorily elucidated.
Although novel SNPs within the CYP1A locus may still be dis-
covered, genetic determinants in other genes that participate in 
the regulation of constitutive and inducible CYP1A2 expression 
should be expected to contribute to interindividual variability. In 
particular the liver-enriched transcription factors HNF4α, HNF1α, 
USF1/2, and the coactivators PGC1α and SRC-1 were shown to 
be involved in constitutive expression of CYP1A2 (Narvaez et al., 
2005; Martínez-Jiménez et al., 2006). Importantly, the aryl hydro-
carbon receptor (AhR) pathway coordinately regulates transcrip-
tion of CYP1 and a battery of additional ADME and other genes 
that constitute the toxicological response to polycyclic aromatic 
hydrocarbons and dioxins (Nebert and Dalton, 2006; Pascussi 
et al., 2008).
While several murine Ah-receptor polymorphisms were shown 
to affect dose–response curves and toxic effects, the existing poly-
morphisms in the human Ah-receptor and other genes of the path-
way have not been systematically investigated as determinants of 
downstream transcription (Okey et al., 2005). Further signaling 
pathways recognized to have an impact on CYP1A2 expression 
include inflammation and immune response, as it is known that 
CYP1A expression is downregulated during sepsis or inflammation 
(Vrzal et al., 2004; Zhou et al., 2008; Tian, 2009).
Here we adopted a pathway-oriented approach to investigate 
the association of polymorphisms in candidate genes involved 
in the transcriptional regulation of CYP1A2 gene expression. We www.frontiersin.org  November 2010  | Volume 1  | Article 129  |  3
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Lincoln, NE, USA). For absolute quantification, a standard curve 
was generated by coanalyzing 250–4000 fmol of recombinantly 
expressed CYP1A2 in insect cell membranes (Becton Dickinson 
Gentest, Heidelberg, Germany) in each experiment. The CYP1A2 
enzyme  activity  was  determined  by  measuring  phenacetin-O-
deethylation as described in Turpeinen et al. (2009).
snP selectIon and genotyPIng Methods
Candidate gene polymorphisms selected for analysis are listed in 
Table S1 in Supplementary Material. SNPs were selected from 
public databases1,2,3,4,5 according to available data on function-
ality, frequency, and linkage based on published research. For 
each gene, SNP selections were complemented by LD (linkage 
disequilibrium)-tag SNPs selected using HaploView6 on HapMap-
CEU SNP population. Genomic DNA was isolated from EDTA 
blood samples using the QIAmp DNA Blood Mini Kit System 
(Qiagen, Hilden, Germany). MALDI-TOF MS (matrix-assisted 
laser  desorption/ionization  time-of-flight  mass  spectrometry) 
genotyping was performed for 85 SNPs distributed across 12 dif-
ferent assays using the MassARRAY Compact system (Sequenom, 
San Diego, CA, USA). Primers for MALDI-TOF MS genotyp-
ing  were  ordered  from  Metabion  International  (Martinsried, 
Germany).  Data  for  additional  78  SNPs  were  obtained  from 
HumanHap300v1.1 chip analysis (Microarray Facility Tübingen 
Services, Tübingen, Germany). Two polymorphisms were geno-
typed using predesigned TaqMan allelic discrimination assays 
(Applied  Biosystems,  Darmstadt,  Germany)  using  a  TaqMan 
7900HT (Applied Biosystems, Darmstadt, Germany). Data for 
four SNPs were kindly provided by E. Schaeffeler (IKP, Stuttgart, 
Germany). Details of primers and genotyping assays are available 
upon request. Approximately 10% of samples within each assay 
were repeated or sequenced in the concerning region to confirm 
genotyping results as a quality control. Generally, less than 0.1% 
discordant results were obtained.
statIstIcal Methods
Statistical analyses were performed using software R-2.11.07 with 
additional  packages  hwde-0.61  and  SNPassoc-1.6-0.  Hardy–
Weinberg p-values were calculated according to Wigginton et al. 
(2005). Minor allele frequency (MAF) and missing values fre-
quency of polymorphisms are given in (Table S1 in Supplementary 
Material). SNPs with MAF < 5% (n = 28) were excluded from 
further analyses. For polymorphisms having less than three het-
erozygotes or homozygotes in the remaining data set (n = 14), 
heterozygotes and homozygotes were combined and compared vs. 
wild-types. From pairs of 100%-linked polymorphisms (n = 5), 
the SNP with the fewest missing values, if present, was chosen. 
Finally, a total of 136 polymorphisms were included in the sta-
tistical analyses.
  control assay (4326314E) from Applied Biosystems (Darmstadt, 
Germany). Normalized values were adjusted to the median value 
of all samples.
CYP1A2 protein expression was analyzed by Western blot in 
liver microsomes. Ten micrograms of protein were separated by 
electrophoresis on a 10% SDS-polyacrylamide gel and blotted onto 
nitrocellulose membranes. Anti-human CYP1A2 monoclonal anti-
body (clone 26-7-5 Invitrogen Panvera, Darmstadt, Germany) and 
IRD800-labeled secondary anti-mouse antibody (Licor, Lincoln, 
NE, USA) were used for detection with an Odyssey system (Licor, 
Table 1 | Population demographics and serum parameters of 150 liver 
donors.
Subgroup  Number
Sex
Male  71
Female  79
Age
≤70  124
>70  26
SmoKiNg hAbiTuSa
Non-smoker  117
Smoker  29
AlCohol CoNSumPTioNa
None  96
≥1 times/week  48
Pre-SurgerY drugS
None  40
P450-inducersb  40
Other drugs  70
Tbili (mg/dl)a
Normal (≤1.2)  125
Elevated (>1.2)  22
ggT (u/l)a
Normal (f: ≤36; m: ≤64)  85
Elevated (f: >36; m: >64)  58
CrP (mg/l)a
Normal (≤8.2)  140
Elevated (>8.2)  7
diAgd
No tumor  3
Primary liver tumors  65
Metastases  82
CholeSTASiSa,c
Non-cholestatic  121
Cholestatic  25
tBili,  serum  total  bilirubin;  GGT,  serum  gamma  glutamyl  transferase;  CRP , 
C-reactive protein; DIAG, diagnosis.
aSample number are not summing up to 150 because of missing information.
bP450 inducers: atorvastatin, beclometasondipropionate, budenoside, estradiol, 
metamizole,  nifedipine,  omeprazole,  pantoprazole,  prednisolone,  simvastatin, 
tamoxifen, vitamin D.
cCholestasis was diagnosed according to Nies et al. (2009).
dDiagnosis groups: no tumor; primary benign and malign liver tumors including 
HCC, cholangiocarcinoma, gallbladder tumor; metastases derived from colon 
carcinomas (65), or other tumors (17).
1www.ncbi.nlm.nih.gov/snp
2www.ncbi.nlm.nih.gov/omim
3www.pharmgkb.org
4www.phosphosite.org
5variome.net
6http://www.broadinstitute.org/haploview/haploview
7www.r-project.orgFrontiers in Pharmacology  |  Pharmacogenetics and Pharmacogenomics    November 2010  | Volume 1  | Article 129  |  4
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the different phenotypes. These values are comparable to previous 
studies by others (Shimada et al., 1994; Jiang et al., 2006; Gunes 
and Dahl, 2008), however compared to our studies on other liver 
drug metabolizing enzymes (e.g., CYPs 2D6, Zanger et al., 2001; 
2B6, Hofmann et al., 2008; 3A4, Wolbold et al., 2003) variation was 
somewhat less pronounced. All three CYP1A2 phenotypes were 
significantly correlated to each other (Figure 2). As expected due 
to common regulation, CYP1A2 expression levels were also highly 
correlated to CYP1A1 (data not shown).
non-genetIc factors InfluencIng cyP1a2 exPressIon
Available documentation to the liver donors included demographic, 
clinical, and self-reported data as shown in Table 1. We used univari-
ate, non-parametric tests to analyze whether any of these parameters 
had an impact on CYP1A2 phenotype. We identified self-reported 
cigaret smoking, pre-surgical drug exposure, liver function, inflam-
mation, diagnosis, and cholestasis as factors being significantly asso-
ciated with microsomal phenacetin O-deethylase activity (Table 3, 
Figure 3). Regular smoking had the strongest impact on all pheno-
type levels and increased CYP1A2 activity, protein and mRNA-levels 
by 1.5-, 1.6-, and 1.5-fold, respectively. Known CYP3A-inducers 
were associated with decreased CYP1A2 activity and protein levels, 
whereas patients treated with other drugs had normal levels. As 
omeprazole had been described as an inducer of caffeine metabolic 
ratio (Rost et al., 1992), we separately analyzed a subgroup of 12 
patients treated with this drug. While mRNA levels were increased by 
1.4-fold (not significant), protein and activity were slightly decreased 
(not significant) compared to controls not exposed to any drug 
(n = 40). Decreased liver function as indicated by elevated serum 
gamma glutamyl transferase (GGT) was associated with slightly 
decreased activity and protein (p < 0.01), but mRNA was unchanged. 
Pathophysiologically increased levels of C-reactive protein (CRP) 
were found in seven liver donors who had strongly decreased levels 
of CYP1A2 activity and protein. Moreover, cholestasis was diagnosed 
in 25 liver donors who also had decreased activity and protein as well 
as a trend for decreased mRNA. Finally, we did not find an associa-
tion between the donor’s sex and CYP1A2 at any phenotype level 
(Figure 3, Table 3), although females had increased protein levels 
(p < 0.05) in the multivariate model (see below). Taken together, 
these data indicated that environmental and other non-genetic fac-
tors have a strong influence on hepatic CYP1A2 phenotype.
snP-selectIon and snP-frequencIes In the study PoPulatIon
We analyzed CYP1A locus SNPs for cis-association and polymor-
phisms in genes of CYP1A2 regulatory pathways for trans-associ-
ation with CYP1A2 phenotype. Selected SNPs of the CYP1A locus 
included the most frequent and the commonly studied CYP1A2 
alleles8 as well as four tag-SNPs selected to represent other hap-
lotypes not previously investigated (Table S1 in Supplementary 
Material). Candidate transcriptional pathway genes included the 
AhR regulatory network (AhR, AhRR, ARNT), liver-enriched tran-
scription factors and coactivators (HNF1α, HNF4α, PPARGC1α, 
SRC-1, USF1), as well as some key regulators and mediators of 
inflammation and immune response (NFκB1, IL1β, IL1RN). We 
also investigated SNPs in the nuclear receptor pathway responsible 
The influence of non-genetic factors on CYP1A2 expression 
was investigated using Kruskal–Wallis tests for categorical and 
Spearman correlations for numerical parameters due to the non-
normality of the phenotypic and non-genetic data. Associations 
between polymorphisms and CYP1A2 expression (mRNA, protein, 
activity) were investigated using the generalized linear model capa-
bilities of the SNPassoc package. In order to satisfy the Gaussian 
distribution condition, phenotypic data were log-transformed and 
data distributions were checked using quantile–quantile plots. The 
SNPassoc package offers four different genetic models:   codominant, 
dominant, recessive, and log-additive. In the codominant, domi-
nant, and recessive models, the genotypic data is treated as a cat-
egorical variable. The codominant model compares wild-types vs. 
heterozygotes vs. homozygotes, while the dominant and recessive 
model  test  wildtypes  vs.  heterozygotes  plus  homozygotes  and 
wildtypes plus heterozygotes vs. homozygotes, respectively. For 
the log-additive model, a numeric variable is created with wild-
type = 0, heterozygote = 1, and homozygote = 2, assuming a linear 
allele-dose effect.
Package SNPassoc was also applied to study associations between 
SNPs and CYP1A2 phenotypes corrected for non-genetic factors. 
For each phenotype studied, the non-genetic correction factors 
were chosen based on linear models between phenotypic data and 
all 10 non-genetic factors considered (age, sex, nicotine and alco-
hol intake, drug exposure, total bilirubin, GGT, CRP, cholestasis, 
diagnosis) as well as models derived from these complete models 
via step-wise model selection using Akaike’s information criterion. 
Non-genetic factors were chosen for correction if the p-value from 
complete and/or reduced models was <0.15. In all linear models, 
we used log-transformed phenotypic data as dependent variable. 
All statistical tests were two-sided and statistical significance was 
defined as p < 0.05.
results
PoPulatIon varIabIlIty of hePatIc cyP1a2
CYP1A2 expression in the 150 Caucasian liver samples varied con-
siderably at the different phenotype levels and was unimodally 
yet not normally distributed (Table 2, Figure 2). Fold-variation 
was highest (196-fold) for mRNA and lowest (35-fold) for enzyme 
activity (Table 2). However the coefficient of variation (cv) as a 
normalized measure of variability was more comparable between 
Table 2 | Population variability of hepatic CYP1A2 expression 
phenotypes (n = 150).
  rNA CYP1A2/  Protein  Phenacetin-O- 
  rPlP0  content  deethylation 
  relative units  pmol/mg  pmol/min/mg
Minimum  0.03  3.62  130.1
Median  1.00  64.7  1442
Maximum  5.88  278.7  4536
Ratio maximum/  196  77 .4  34.9 
minimum
Normal distribution  No  No  No
Coefficient of  77 .2  69.3  56.2 
variation (cv, %) 8http://www.cypalleles.ki.sewww.frontiersin.org  November 2010  | Volume 1  | Article 129  |  5
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genotyPe–PhenotyPe correlatIon analysIs
Univariate analysis
A total of 136 SNPs with MAF > 5% were further investigated for 
association with phenotypic data by univariate analysis, applying 
four different genetic models (co-dominant, dominant, recessive, 
or log-additive, see Materials and Methods). Without correction for 
non-genetic factors, this resulted in a total of 25, 16, and 16 signifi-
cant associations at p < 0.05 for activity, protein, and mRNA, respec-
tively. A graphical summary of these results is shown in Figure 4.
The log-additive model is based on the assumption of a gene-
dose effect, such that heterozygotes are phenotypically intermedi-
ate between homozygous wild-types and mutants. Limiting the 
results to this mechanistically most plausible genetic model and 
  restricting to the strongest significant associations with p < 0.01 
revealed a total of 11 univariate associations showing a significant 
linear trend for any one or more phenotypes (Table 4). However, 
the SNPs in AhRR and HNF1α were pairwise linked with up 
to  95%  (rs2241598/rs10078;  rs1169300/rs2464196;  rs1169306/
rs735396). The SNPs in RXRα and VDR were independent. The 
SNP rs2134688 in the ARNT gene was consistently associated 
for induction of CYP2 and CYP3 enzymes (PXR, CAR, RXR, RAR, 
VDR). These genes were selected for exploratory reasons as direct 
interaction with CYP1A2 has not been shown.
The selected SNPs were located in intron regions (98), exonic 
regions (23 non-synonymous, 9 synonymous), promoters (12) 
and up- or downstream of the genes (27). In total we genotyped 
15 SNPs in the CYP1A1/2 locus and 154 SNPs in 16 candidate 
genes (Table S1 in Supplementary Material). Of these, 4 and 10 
SNPs, respectively, were not detected in any of the samples and 
5 were in complete linkage to other SNPs and were therefore not 
included in further analyses. Hardy–Weinberg equilibrium test 
resulted in p > 0.001 for all tested SNPs (values see Table S1 in 
Supplementary Material).
The calculated SNP frequencies in our Caucasian liver donor 
population correlated well (Spearman rS = 0.92) with frequency data 
compiled from dbSNP database for the HAPMAP-CEU population 
(n = 153) (Figure S1 in Supplementary Material). Fourteen of the 
analyzed SNPs were rare (MAF < 5%) and five of these were located 
in the CYP1A locus. The remaining had MAFs between 5 and 20% 
(n = 33) and 103 SNPs appeared with frequencies above 20%.
Figure 1 | overview of known pathways for transcriptional regulation at 
the CYP1A2 promoter. The scheme shows the 23.3-kb intergenic region 
between the head-to-head oriented CYP1A1 and 1A2 genes on chromosome 
15q24.1. Binding elements located within the common promoter region may thus 
be shared for transcriptional regulation of both genes. Pathways for constitutive 
and tissue specific expression are shown by red symbols at the bottom and 
include the liver-enriched transcription factors HNF4α and HNF1α and their 
coactivators PGC1α and SRC-1, as well as basic transcriptional activators SP-1 and 
USF-1 (Quattrochi et al., 1994; Chung and Bresnick, 1997; Narvaez et al., 2005; 
Martínez-Jiménez et al., 2006). Top-middle: Genes selected for the AhR-pathway 
include the ligand-binding receptor AhR, the AhR nuclear translocator ARNT, and 
the AhR regulator AhRR. The activated ligand bound form of AhR is complexed 
with two heat-shock proteins hsp90 and AIP , and co-chaperone p23, which help to 
correctly fold and stabilize the AhR and prevent inappropriate trafficking to the 
nucleus (Petrulis et al., 2000). Upon heterodimerization with activated AhR, the 
ARNT/AhR complex translocates to the nucleus to activate transcription from 
AHRE- and XRE-motifs (Okino et al., 2007). AhRR competes with AhR for ARNT 
binding, resulting in inhibition of AhR-mediated signal transduction. Top-right: 
Under pathophysiological conditions of inflammation, inflammatory cytokines like 
IL1ß and TNFα or chronic oxidative stress (H2O2) activate NFκB which in turn 
inhibits AhR activity thus leading to reduced CYP1A expression. This pathway can 
be blocked by competing antagonists like IL1RN (Tian et al., 1999; Vrzal et al., 
2004; Zhou et al., 2008). Top-left: Exploratory pathways involving possible crosstalk 
to other known xenobiotic transcriptional regulation networks are indicated by 
PXR/RXRα, CAR/ RXRα, VDR/ RXRα heterodimers. Proteins designated in black 
were not included in this study.Frontiers in Pharmacology  |  Pharmacogenetics and Pharmacogenomics    November 2010  | Volume 1  | Article 129  |  6
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with reduced levels of all three phenotypes; SNP rs2241598 in 
the AhRR gene was consistently associated with increased levels 
as indicated in Table 4 and Figure 5. Seven SNPs in the HNF1α, 
IL1β, SRC-1, and VDR genes were associated with unidirectional 
changes in activity and protein, one further AhRR SNP (rs10078) 
was associated with increased activity. Besides the ARNT SNP men-
tioned above, only one SNP (rs3818740 in RXRα) was correlated 
to decreased mRNA.
Of note, none of the SNPs of the CYP1A locus were among 
these most significant relationships when our MAF limit of 5% 
was applied. However, for the CYP1A2 promoter SNP rs2069522 
(MAF = 3.7%), we found a trend to lower protein and mRNA 
expression (data not shown).
Multivariate analysis
The association between each of the 136 polymorphisms and each 
phenotype, corrected for chosen non-genetic factors (activity and 
protein: age, sex, nicotine intake, total bilirubin, CRP, diagnosis; 
mRNA: sex, nicotine intake, drug treatment, total bilirubin, CRP, 
diagnosis) was tested by R-package SNPassoc. As described in 
Section “Statistical Methods,” we selected those non-genetic   factors 
Figure 2 | Spearman correlations and population distribution of hepatic 
CYP1A2 phenotypes. CYP1A2 mRNA was determined by a specific TaqMan 
real-time RT-PCR assay, protein was determined by Western blot and enzyme 
activity was measured by LC-MSMS analysis of phenacetin-O-deethylation in 
human liver microsomes (n = 150). Results are means of duplicate 
measurements. (A–C) Spearman rank correlation analysis; blue: non-smokers; 
red: smokers. The correlation coefficients were (A) rs = 0.36; (b) rs = 0.47; 
(C) rs = 0.83. The statistical significance for all comparisons was p < 0.0001. (d) 
Histogram showing population distributions for enzyme activity (red), protein 
(blue), and mRNA (green) using 20 bins over the entire phenotype range.
Table 3 | influence of non-genetic factors on CYP1A2 phenotype.
Non-genetic  Correlation  mrNAc  Proteinc  Activityc 
factora  testb
Sex  K  0.26  0.68  0.99
Age  S  0.27  0.045  0.24
NIC  K  0.018  0.001  0.0004
ALC  K  0.30  0.50  0.71
IND  K  0.38  0.025  0.03
BILI  K  0.001  0.0002  0.0005
GGT  K  0.11  0.001  0.009
CRP  K  0.32  0.015  0.03
DIAG  K  0.08  0.09  0.009
Chol  K  0.06  0.008  0.004
aNIC, nicotine consumption: non smokers vs. smokers (>1 cigarets/day); ALC, 
alcohol consumption: none vs. >1 times/week; IND, exposure to known inducers 
of P450; BILI, serum total bilirubin; GGT, serum gamma glutamyl transferase; 
CRP , C-reactive protein; DIAG, diagnosis; Chol, cholestasis.
bKnuskal-Wallis (K) or  Spearman correlation (S) test.
cp-Values for univariate analyses using the given correlation test. Results were 
not corrected for multiple testing.www.frontiersin.org  November 2010  | Volume 1  | Article 129  |  7
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Figure 3 | CYP1A2 enzyme activity in population subgroups. The liver 
donors (n = 150) were divided into subgroups according to available clinical 
documentation on environmental exposures and other non-genetic factors: SEX, 
(m) male, (f) female; NIC, nicotine consumption, (−) non-smokers (+) smokers 
(>1 cigarets/day); ALC, alcohol consumption (−) none (+) >1 times/week; IND, (n) 
no drugs, (+) known inducers of P450, (o) other drugs; BILI, serum bilirubin, (n) 
value in normal range, (e) elevated value; GGT, serum gamma glutamyl 
transferase, (n) value in normal range, (e) elevated value; CRP , C-reactive protein, 
(n) value in normal range, (e) elevated value; DIAG, diagnosis leading to liver 
resection, (n) no tumor, (L) primary liver tumor, (M) metastasis of other primary 
tumor; Chol, cholestasis, (−): non-cholestatic, (+) cholestatic. For results on 
mRNA and protein and for statistical information see Table 3. Boxes are defined 
by the 25 and 75% quantile. The median is displayed as vertical line inside of the 
box. Whiskers are defined as the lowest/highest data point still within 75%/25% 
quantile ± 1.5 times the interquantile range (75–25% quantile). Outliers are 
shown as dots.
for correction with p < 0.15 in (a) linear models with all 10 non-
genetic factors and/or (b) models derived from these models by 
step-wise model selection.
As summarized in Table 4, all SNPs associated to any phenotype 
in the univariate analysis remained significant (p < 0.05) in the 
multivariate analysis except rs1169300 in HNF1α which lost asso-
ciation to activity. Both AhRR SNPs and two VDR SNPs remained 
significantly associated to activity with p < 0.01.
The  step-wise  model-selection  method  was  furthermore 
applied  to  determine  the  contribution  of  genetic  and  non-
genetic factors to CYP1A2 variability at each phenotype level 
(Figure 6). For this purpose, we first defined initial linear models 
with (a) non-genetic factors only (vide Statistical Methods), (b) 
all polymorphisms with p < 0.05 in the univariate or multivariate 
log-additive models described above, and (c) with both, SNPs and 
non-genetic factors, where the latter were selected as described 
above. The application of stepwise model-selection using Akaike’s 
information criterion resulted in final linear models containing 
those SNPs and non-genetic factors which explain each of the 
phenotypes best. As graphically displayed in Figure 6, the genetic 
polymorphisms identified in our candidate genes explained a 
slightly larger fraction of the total variability than the non-ge-
netic factors at each phenotype level. The fraction explained was 
highest for CYP1A2 activity (42%), however, in total less than 
half of the hepatic CYP1A2 variability could be explained by the 
multivariate models.
Multiple testing correction
To  correct  for  multiple  testing  we  applied  the  Benjamini–
Hochberg adjustment procedure controlling the false discovery 
rate (FDR) (Benjamini and Hochberg, 1995). With a FDR < 0.05 
only the ARNT SNP rs2134688 and the RXRα SNP rs3818740 
remained significantly associated with decreased mRNA in the 
univariate analysis.
dIscussIon
In this study we searched for genetic polymorphisms that could 
explain the high heritability that has been proposed for CYP1A2 
based on a classical twin-study that compared monozygotic and 
dizygotic twin-pairs phenotyped for the prototypic CYP1A2 sub-
strate caffeine (Rasmussen et al., 2002). Several previous studies 
attempted to identify genetic or epigenetic markers for CYP1A2 
by concentrating on the CYP1A locus on chromosome 15 (Jiang 
et al., 2006; Ghotbi et al., 2007; Gunes and Dahl, 2008). However, 
the results of these former studies have been disappointing in that 
the few genetic markers identified are unable to explain more than a 
tiny fraction of the interindividual variability of this enzyme (Jiang 
et al., 2006) and most of them are still controversial (Zanger et al., 
2008). One part of our study dealing with polymorphisms at the 
CYP1A locus confirmed these findings. We studied 15 well-selected 
polymorphisms that have been previously associated with changes 
in phenotype or expression, or represent possible tag-SNPs not 
studied before. None of these SNPs was significantly associated 
with CYP1A2 activity or protein expression, and only for one rare 
promoter SNP a trend to lower protein and mRNA levels was found. 
A recent genome-wide study that analyzed a total of 782,476 unique 
SNPs in 466 liver samples also failed to detect any novel markers of 
CYP1A2 expression (mRNA) or activity within the CYP1A locus 
(Yang et al., 2010). Future studies by next-generation sequencing 
and initiatives like the 1000-genomes project9 will reveal novel 
polymorphisms in the CYP1A locus that can be tested as markers 
for phenotype. However, given the experience and amount of work 
done so far, it seems very unlikely that cis-associations make an 
important contribution to the overall variability of this enzyme.
In our study we have therefore concentrated on other genes and 
on various non-genetic factors as possible influential factors for 
expression and function of CYP1A2 in liver. By taking advantage 
9http://www.1000genomes.org/Frontiers in Pharmacology  |  Pharmacogenetics and Pharmacogenomics    November 2010  | Volume 1  | Article 129  |  8
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  categorized as typical inducers of CYP2 and CYP3A genes, includ-
ing nifedipine, atorvastatin, or glucocorticoids, had a repressive 
effect on CYP1A2. We also confirmed a moderate inducing effect 
of omeprazole (Rost et al., 1992), although this was not significant 
at the level of mRNA. We furthermore confirmed that inflamma-
tion processes have a decreasing effect on CYP1A2 expression 
(Congiu et al., 2009). The finding that measurement of CRP and 
serum bilirubin can predict lower CYP1A2 is new, to our knowl-
of the detailed documentation available to the samples of our liver 
bank, we were able to study the influence of diverse environmen-
tal and other non-genetic factors at unprecedented detail. It was 
expected, based on previous work (Sesardic et al., 1988; Bock 
et al., 1994; Ghotbi et al., 2007), that CYP1A2 will be increased 
in cigaret smokers, and we confirmed this with about 1.5-fold 
elevated expression at all levels. Another environmental factor 
analyzed concerns pre-surgical drug exposure. Interestingly, drugs 
Figure 4 | Summary of univariate analysis of all tested SNPs (n = 136) in relation to CYP1A2 activity (A), protein (b), and mrNA (C). Each dot represents the 
minimum p-value from all four genetic models (codominant, dominant, recessive, log-additive). Genes are ordered due to chromosomal location. The dotted line 
marks the 5% significance level p-values are not adjusted for multiple testing.www.frontiersin.org  November 2010  | Volume 1  | Article 129  |  9
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Figure 5 | genotype–phenotype correlations for CYP1A2 activity, protein, and mrNA exemplarily for some significant SNPs. Genotypes are indicated by A 
(major allele) and B (minor allele). N, number of individuals per group; numbers for the three genotypes do not add up to 150 in each case due to missing values. 
Selected representative results are shown as box-and-whisker plots with outliers for significant SNPs taken from Table 4.Frontiers in Pharmacology  |  Pharmacogenetics and Pharmacogenomics    November 2010  | Volume 1  | Article 129  |  10
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edge. Interestingly, a case report on increased serum clozapine 
levels after bacterial infection indicated a similar effect (Raaska 
et al., 2002). Furthermore, we also found that other pathophysi-
ological states of the liver are associated with decreased CYP1A2 
expression. Thus, cholestasis and/or elevated GGT levels were 
correlated with decreased CYP1A2 activity, protein and mRNA 
expression by 1.2-, 1.6-, and 1.3-fold, respectively. To our knowl-
edge this has not been reported before for humans. Reduced activ-
ity of CYP1A2 was however found in rats with drug induced 
cholestasis (Bramow et al., 2001) and following biliary obstruc-
tion (Fukushima et al., 2008). A further pathophysiological factor 
influencing CYP1A2 phenotype was identified by analyzing the 
reasons leading to the surgical liver resection (diagnosis). The 
reason for elevated levels of CYP1A2 in livers with metastases of 
extrahepatic primary tumors, predominantly colon carcinoma, is 
currently unknown. Finally, we did not find convincing evidence 
for a sex-related expression difference, as only the multivariate 
model indicated increased protein in females. Previous in vivo 
studies have indicated higher activity of CYP1A2 in males vs. 
females based on in vivo measured probe drugs (Relling et al., 
1992; Rasmussen and Brøsen, 1996; Scandlyn et al., 2008). The 
absence of convincing sex-related differences in our study thus 
contradicts these earlier findings but is in agreement with the 
recent study of 466 Caucasian livers, which also failed to detect 
an unequivocal sex-effect on CYP1A2 activity (Yang et al., 2010). 
Taken together these data confirm and further extend our knowl-
edge about environmental and pathophysiological factors influ-
encing CYP1A2 activity and expression in human liver.
For the genetic part of our study we applied a pathway-oriented 
approach and concentrated on transcriptional regulatory routes, 
because CYP1A2 expression is highly variable and has been shown 
to be affected by several constitutive and inducible as well as inhibi-
tory pathways (summarized in Figure 1).
Figure 6 | Contribution of genetic and non-genetic factors to CYP1A2 
expression. Percentage of the total CYP1A2 variation as explained by 
multivariate linear models containing only non-genetic factors (green), only 
genetic factors (blue), or both combined (yellow). The bars indicate the 
coefficient of determination adjusted for the number of factors in the 
different models. As described in the text, the linear models were obtained 
by a step-wise model selection procedure using Akaike’s information 
criterion.
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both remaining significant in the multivariate model. From these 
the tag SNP rs1540339 is located in an intron and rs10735810 
(new rs2228570) is the so-called “FokI” variation often included 
in pharmacogenomic studies of diseases (Guo et al., 2006; Purdue 
et al., 2007; Heist et al., 2008). The site is affecting the N-terminus 
of VDR protein altering the transcriptional start site resulting in a 
shortened variant with higher transcriptional activity (Uitterlinden 
et al., 2004). This may explain our finding of increased protein and 
activity of CYP1A2 associated with that polymorphism, suppos-
ing a direct action of VDR in CYP1A2 regulation at unidentified 
hormone response elements.
When  all  relevant  genetic  and  non-genetic  factors  were 
  combined in a multivariate model, they explained 42, 38, and 
33% of CYP1A2 variation at activity, protein, and mRNA levels, 
respectively (Figure 6). While this represents a significant con-
tribution it must be realized that over 50% of the variation in 
CYP1A2 remains still unexplained and particularly the proposed 
high heritability requires additional genetic factors for explana-
tion. A different strategy that can be taken is by genome-wide 
association analysis using high-density microarray technology. 
This approach is principally hypothesis-free and therefore can 
detect entirely novel relationships (Daly, 2010; Motsinger-Reif 
et al., 2010). In a recent genome-wide study of liver gene expres-
sion in a liver bank comprising over 400 donors, Schadt et al. 
(2008) identified 3,210 expression quantitative trait loci, i.e., 
significant genotype–phenotype relationships. In a follow-up 
study, Yang et al. (2010) identified a number of novel trans-
acting genes with highly significant trans-associations to CYP1A2 
activity. None of them was among our selection of candidate 
genes. The potential role of these genes for CYP1A2 regulation 
awaits further elucidation.
conclusIon
We performed the first pathway-oriented approach to investigate 
whether polymorphisms in genes regulating the expression and 
function of CYP1A2 in human liver in constitutive, ligand-induci-
ble, and pathophysiological manner can explain in part the assumed 
high heritability of CYP1A2 phenotype. The results are promising 
in that several polymorphisms in the ARNT, AhRR, HNF1α, IL1β, 
SRC-1, RXRα, and VDR genes seem to influence hepatic CYP1A2 in 
a consistent way and that explain more of the phenotypic variability 
than non-genetic factors including smoking, drug treatment, and 
inflammation. We think that this represents a significant advance 
for the pharmacogenomics of this important enzyme.
However, as more than 50% of the variation is still unexplained, 
additional genetic factors must be assumed. The identified can-
didate SNPs should now be assessed in larger in vivo studies to 
evaluate their potential clinical value.
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From these pathways 136 SNPs in 16 genes and the CYP1A locus 
were included in our final statistical analysis. The 13 strongest 
significant associations revealed by univariate and multivariate 
analysis comprise four SNPs in the ARNT, RXRα, and SRC-1 gene 
associated with lower expression and/or activity. Only rs2134688 
in the ARNT gene consistently showed decreased levels in all phe-
notypes. This SNP is located in an intron and is member of a 
large LD block of about 550 kb including SNPs in the promoter 
region of ARNT and also upstream and downstream neighboring 
genes. Das et al. (2008) previously described this site in context of 
acute insulin response in that the insulin secretion in non-diabetic 
subjects may be altered. The others were intronic SNPs in SRC-1 
(rs2119115) and in RXRα (rs3818740, rs3132297), which all were 
selected as “tag” SNPs representing possible new haplotypes for 
the genes because of linkage to a set of other polymorphisms in 
the gene region and throughout the promoter. They have not been 
analyzed before and may influence their own mRNA expression, 
thus resulting in lower transcription of CYP1A2. Of note, two of 
these disabling SNPs (rs2134688 in ARNT, rs3818740 in RXRα) 
remained significant after multiple testing correction for CYP1A2 
mRNA expression.
Interestingly, all other SNPs (n = 9) with strong association 
to CYP1A2 phenotype caused increased levels for protein and/
or activity, except one in AhRR (rs2241598), which showed an 
additional effect on mRNA level. This SNP is positioned in the 3′ 
UTR of AhRR, indicating a possible post-transcriptional regula-
tion of the inhibitor AhRR by miRNAs and thus having a positive 
effect on CYP1A2 expression. The other SNP genes belonged to 
different regulatory pathways (basal/constitutive, inducible, and 
cytokine) pointing to the complex network of transcriptional 
regulation pathways of CYP1A2 expression. The four polymor-
phisms in the HNF1α gene, consisting of two pairs of strongly 
linked  SNPs,  were  consistently  associated  with  significantly 
increased activity and protein levels at least in the univariate 
analysis. Besides three intronic positions (rs1169300, rs1169306, 
rs735396), one SNP (rs2464196) affected an amino acid serine 
(S) at position 487 by change to asparagine (N), which in turn 
should not be damaging to the HNF1α protein, according to 
an analysis with PolyPhen10. All four SNPs have been included 
in previous studies on plasma CRP levels, and S487N was sig-
nificantly associated with lower CRP and GGT levels (Reiner 
et al., 2008, 2009; Ridker et al., 2008) indicating a connection to 
inflammation signaling.
In our study CYP1A2 protein and activity was influenced by 
an exon SNP in IL1ß (rs1143634) affecting codon 105, but keep-
ing amino acid phenylalanine. This SNP was included in some 
recent studies and was associated with diseases in Japanese (lung 
cancer: Kiyohara et al., 2010) and Caucasians (schizophrenia: Xu 
and He, 2010).
RXRα-participating heterodimers of the xenobiotic translational 
regulation pathways were included in this study for exploratory 
reasons. As discussed above, both SNPs in RXRα were associated 
uniformly  with  decreased  CYP1A2  expression.  Of  the  nuclear 
receptors included two SNPs in VDR (NR1I1) were significantly 
associated to higher protein and activity in the univariate model, 
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Table S1 | included SNPs, genotyping methods and frequencies.
gene  SNP rs  Allele/  nt  effect  Type  mAF  mAFb  hWp  missing   method  reference 
    position        publisheda      values (%)
CYP1A2 Chr15; Nm_000761
  rs2069514  *1C  G > A    p  0.081  0.007  1  0  Tq-AD  Nakajima et al. (1999), 
                    Abnet et al. (2007)
  rs2069522    C > T    p  0  0.037  0.173  0  Maldi  Bethke et al. (2007)
  rs12720461  *1K  C > T    p  0  0.003  1  0  Maldi  Aklillu et al. (2003)
  rs762551f  *1F  A > C    p  0.308  0.32  0.455  0  Maldi  Han et al. (2002)
  rs72547513  *11  C > A  F186L  nc  No data  0    0  Maldi  Murayama et al. (2004), 
                    Pucci et al. (2007)
  rs56276455  *3  G > A  D348N  nc  No data  0.003  1  0  Maldi  Zhou et al. (2009)
  rs72547516  *4  A > T  I386F  nc  No data  0    0  Maldi  Zhou et al. (2009)
  rs56107638  *7  G > A    i  (0.003)  0    0  Maldi  Allorge et al. (2003)
  rs28399424  *6  C > T  R431W  nc  No data  0    0  Maldi  Zhou et al. (2009)
  rs2470890    C > T  N516  sc  0.358  0.387  0.492  0  Maldi  Gunes and Dahl (2008)
  rs4886406    A > C    3′  0.292  0.323  0.34  4  ILM 
CYP1A1 Chr15; Nm_000499
  rs2470893    G > A    5′  0.275  0.294  0.029  1.3  ILM 
  rs2472299f    G > A    5′  0.308  0.319  0.571  0.7  ILM 
  rs4646421    C > T    p  0.075  0.094  0.618  0.7  ILM 
  rs1048943  *2B/C  A > G  I462V  cn  0.042  0.027  0.143  0.7  Tq-AD  Hayashi et al. (1991),  
                      Zhang et al. (1996)
Ahr (ArYl hYdroCArboN reCePTor) Chr7; Nm_001621
  rs10247158    A > T    5′  0.152  0.13  1  0  Maldi  Bin et al. (2008)
  rs10250822    T > C    5′  0.2  0.217  0.81  0  Maldi  Bin et al. (2008)
  rs4719497    T > C    5′  0.1  0.108  1  1.3  ILM 
  rs2282885    A > G    i  0.347  0.413  0.736  0  Maldi  Bin et al. (2008)
  rs1476080    T > G    i  0.325  0.343  0.21  0  Maldi  Bin et al. (2008)
  rs4236290    T > C    i  0.125  0.122  0.697  2  ILM 
  rs6960165    A > G    i  0.196  0.205  1  0.7  Maldi  Bin et al. (2008)
  rs2158041    C > T    i  0.183  0.203  1  1.3  ILM  Chen et al. (2009)
  rs7811989    G > A    i  0.233  0.233  1  0  Maldi  Bin et al. (2008)
  rs2066853    G > A  R554K  nc  0.075  0.1  1  0  Maldi  Long et al. (2006), 
                    Abnet et al. (2007), 
                    Wong et al. (2001)
                    Cauchi et al. (2001); 
                      Merisalu et al. (2007)
  rs4986826    G > A  V570I  nc  0  0    0.7  Maldi  Wong et al. (2001)
Ahrr(ArYl hYdroCArboN reCePTor regulATor); Chr5; Nm_020731
  rs3756712    T > G    i  0.342  0.361  0.723  1.3  ILM 
  rs4957018    A > G    i  0.275  0.322  0.453  0.7  ILM 
  rs3734145    C > T    i  0.25  0.258  0.052  0.7  ILM 
  rs4957028    T > C    i  0.424  0.463  1  1.3  ILM 
  rs908114    A > G    i  0.383  0.329  0.853  2.7  ILM 
  rs2721020    G > A    i  0.225  0.232  1  0.7  ILM 
  rs7731963    C > A    i  0.375  0.411  0.389  6.7  ILM 
  rs2292596    C > G  P189A  nc  0.412  0.373  0.296  0  Maldi  Watanabe et al. (2001)
  rs34453673    G > C  D641H  nc  0.31  0.403  0.612  0  Maldi  Cauchi et al. (2003)
  rs10078    A > C    3′u  0.2  0.218  0.81  0.7  ILM 
  rs2241598    C > T    3′  0.183  0.211  1  0.7  ILM 
ArNT (hiF1β; ArYl hYdroCArboN reCePTor NuCleAr TrANSloCATor) Chr1; Nm 001668
  rs2292166    C > T    5′  0.217  0.282  0.015  0.7  ILM 
  rs7412746    C > T    5′  0.475  0.419  0.737  1.3  ILM 
  rs11204735    C > T    i    0    0.7  Maldi  Das et al. (2008)
  rs2134688    A > G    i  0.142  0.13  0.716  0  Maldi  Das et al. (2008)
  rs2228099e    G > C  V189  sc  0.35  0.307  0.255  0  Maldi  Kayano et al. (2004)
  rs1889740e    G > A    i  No data  0.307  0.255  0  Maldi  Das et al. (2008)
  rs10305724    C > T    i  0.125  0.057  0.383  0.7  ILM 
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CAr (Nr1i3; CoNSTiTuTiVe ANdroSTANe reCePTor) Chr1; Nm_00177469
  rs6686001    C > A    i  0.13  0.143  0.739  0  Maldi 
  rs3003596    T > C    i  0.49  0.363  0.289  0  Maldi 
      C > T    i  0.242  0.19  0.063  0  Maldi  Oliver et al. (2010)
    398T > G  T > G  V133G  nc  No data  0      Maldi  Ikeda et al. (2005)
  rs2307424    C > T  P180  sc  0.471  0.311  0.252  1.3  ILM  Oliver et al. (2010)
  rs2307418    A > C    i  0.183  0.153  0.529  4  ILM 
  rs4073054    G > T    i  0.408  0.476  0.247  2  ILM  Oliver et al. (2010)
hNF1α (TCF1; hePAToCYTe NuCleAr FACTor 1 homeobox A) Chr12; Nm_000545
    -58  A > C    p  No data  0    0.7  Maldi  Gragnoli et al. (1997)
  rs1169288    A > G  I27L  nc  0.283  0.393  0.864  0  Maldi  Holmkvist et al. (2006), 
                    Cauchi et al. (2008), 
                    Ryffel (2001)
  rs1800574    C > T  A98V  nc  0.029  0.023  1  0  Maldi  Giuffrida et al. (2009)
  rs1169300    G > A    i  0.292  0.315  0.851  0.7  ILM  Ridker et al. (2008)
  rs2071190    T > A    i  0.22  0.19  1.0  0  Maldi  Weedon et al. (2005)
  rs1169302    T > G    i  0.45  0.433  0.318  0.7  ILM  Ridker et al. (2008)
  rs2464196    G > A  S487N  nc  0.292  0.317  1  0  Maldi  Ridker et al. (2008)
  rs1169306    C > T    i  0.375  0.377  1  0  Maldi 
  rs1169307    T > C    i  0.392  0.426  0.319  0.7  ILM 
  rs735396    A > G    i  0.383  0.382  0.727  1.3  ILM  Reiner et al. (2008), 
                    Ridker et al. (2008)
hNF4 α (Nr2A1; hePAToCYTe NuCleAr FACTor 4 AlPhA) Chr20; Nm_000448
  rs4810424    G > C    p  0.164  0.157  0.364  0  Maldi  Bagwell et al. (2005)
                    Sookoian et al. (2010)
  rs2144908    G > A    p  0.183  0.16  0.539  0  Maldi  Lamba et al. (2008), 
                    Muller et al. (2005), 
                    Holmkvist et al. (2008), 
                    Black et al. (2008)
  rs2868094    T > C    p  0.317  0.28  0.316  0  Maldi 
  rs6031544    C > T    p  0.283  0.289  0.842  0.7  ILM  SNP@promoter
  rs3212183    T > C    i  0.413  0.45  0.0029  0  Maldi  Muller et al. (2005)
  rs6073432    A > C    i  0.309  0.307  0.057  0  Maldi 
  rs13041396    C > G    i  0.24  0.207  0.133  0  Maldi 
    c.379  C > T  R127W  nc  No data  0      Maldi  Lausen et al. (2000)
  rs1800961    C > T  T139I  nc  No data  0.02  0.05  0  ILM  Sookoian et al. (2010), 
                    Lu et al. (2008)
    c.460  C > T  R154X  nc  No data  0      Maldi  Lausen et al. (2000)
  rs6103731    G > A    i  0.484  0.423  0.404  0  Maldi 
  rs3818247    G > T    i  0.39  0.367  0.86  0  Maldi  Love-Gregory et al. (2004)
il1β(iNTerleuKiN 1 beTA) Chr2; Nm 000576
  rs1143627    C > T    p  0.367  0.293  0.238  0  Maldi  Liu et al. (2010)
  rs1143634    C > T  F105  cs  0.223  0.22  0.811  0  Maldi 
il1rN (iNTerleuKiN 1 reCePTor ANTAgoNiST) Chr2; Nm_000577
  rs2637988    G > A    i  0.392  0.399  0.733  0.7  ILM 
  rs3213448    G > A    i  0.117  0.128  0.469  0.7  ILM 
  rs419598    T > C  A57  Cs  0.275  0.287  0.84  4.7  ILM 
  rs315952    T > C  S133  cs  0.258  0.295  0.555  0.7  ILM 
  rs397211    T > C    3′  0.314  0.342  0.856  0.7  ILM 
NFKb1 (NuCleAr FACTor NF-KAPPA-b P105 SubuNiT) Chr4; Nm_003998
  rs28362491    del >     5′  0.34  0.361  0.019  2  Maldi  Karban et al. (2004) 
     ATT G
  rs3774937    T > C    p/i  0.367  0.326  0.853  0.7  ILM 
  rs230530    T > C    i  0.364  0.446  0.403  2  ILM 
  rs4647992    C > T    i  0.067  0.047  0.344  0.7  ILM 
  rs230526    C > T    i  0.467  0.396  0.230  0.7  ILM  Liu-Mares et al. (2007)
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  rs4648022    C > T    i  0.067  0.077  1  0.7  ILM  Cerhan et al. (2008)
  rs1598859    T > C    i  0.343  0.379  1  3.3  ILM  Liu-Mares et al. (2007)
  rs4648072    A > G  M507V  nc  0.075  0.013  0.049  0.7  Maldi  SIFT-score 0.44
  rs1609798    C > T    i  0.331  0.329  1  0.7  ILM 
  rs997476    C > A    3′  0.1  0.057  0.068  1.3  ILM 
  rs10489113    A > G    3′  0.225  0.182  1  1.3  ILM 
PgC1α (PPArgC1α; PeroxiSome ProliFerATor-ACTiVATed reCePTor gAmmA CoACTiVATor 1-AlPhA) Chr4; Nm_013261
  rs4361373    C > T    i  0.192  0.141  1  0.7  ILM 
  rs4550905    A > G    i  0.325  0.27  0.676  1.3  ILM 
  rs6448226    A > G    i  0.375  0.34  0.465  2  ILM 
  rs2970853    G > A    i  0.308  0.211  0.218  2  ILM  Juang et al. (2010)
  rs2932976    G > A    i  0.271  0.314  0.334  3.3  ILM 
  rs2970847    C > T  T394  sc  0.208  0.153  1  0  Maldi  Bhat et al. (2007), 
                    Juang et al. (2010)
  rs8192678    G > A  G482S  nc  0.367  0.322  0.708  2.7  Maldi  Deeb and Brunzell (2009), 
                    Wang et al. (2007)
  rs2932965    G > A    i  0.25  0.171  0.771  0.7  ILM 
  rs12650562    G > A    i  0.435  0.426  0.74  0.7  ILM 
Pxr (Nr1i2; PregNANe x reCePTor) Chr3; Nm_003889
  rs1523130    G > A    5′  0.407  0.423  0.403  0  Maldi  Lamba et al. (2008)
  rs3814055i    C > T    5′  0.4  0.417  0.4  0  Maldi*  Zhang et al. (2001)
  rs1523127    A > C    5′  0.408  0.42  0.314  0  Maldi*  Zhang et al. (2001), 
                    King et al. (2007)
  rs2276706i    G > A    i  0.39  0.417  0.4  0  Maldi  Zhang et al. (2001)
  rs4234666    C > G    i  0.318  0.233  1  0  Maldi 
  rs1403527    T > G    i  0.11  0.226  1  2.7  ILM 
  rs1403526    A > G    i  0.242  0.341  0.068  1.3  ILM 
  rs55764158    C > A    i  0.293  0.29  0.078  0  Maldi  Lamba et al. (2008)
  rs16830505    A > G    i  0.15  0.117  0.694  0.7  ILM 
  rs2472677    C > T    i  0.5  0.427  0.096  0  Maldi  Lamba et al. (2008)
  rs4440154    C > T    i  0.35  0.384  0.119  2  ILM 
  rs2461823    T > C    i  0.35  0.379  0.164  0.7  ILM 
  rs13059232    T > C    i  0.358  0.379  0.217  3.3  Maldi  Lamba et al. (2008)
    69245C > T  C > T    i  No data  0.077  1    Maldi  Lamba et al. (2008)
  rs7643645    A > G    i  0.43  0.363  0.598  0  Maldi  Lamba et al. (2008)
  rs12721613  *2  C > T  P27S  nc  0  0    0.7  Maldi  Hustert et al. (2001)
  rs12721607  *3  G > A  G36R  nc  0.03  0.027  1  0  Maldi  Hustert et al. (2001)
  rs72551372  *10  G > A    nc  No data  0    0.7  Maldi  Hustert et al. (2001)
  rs72551374    A > G    i  No data  0    0.7  Maldi  Hustert et al. (2001), 
                    Lim and Huang (2007)
  rs3732357    G > A    i  0.225  0.336  0.009  0.7  ILM 
  rs6785049    A > G    i  0.302  0.413  0.018  0  Maldi*  Zhang et al. (2001)
  rs2276707    C > T    i  0.058  0.22  0.641  0  Maldi*  Zhang et al. (2001)
  rs3732359    G > A    3′u  0.075  0.277  0.091  6  Maldi  Oleson et al. (2010)
  rs1054191    G > A    3′u  0.233  0.14  0.079  0  Maldi  Zhang et al. (2001)
  rs3814057    T > C    3′u  0.188  0.218  0.81  0.7  Maldi  Zhang et al. (2001)
rArα (Nr1b1; reTiNoiC ACid reCePTor AlPhA) Chr17; Nm_001033603
  rs13706g    G > A  V441Id 5 ′d  0.142  0.094  0.618  0.7  ILM 
  rs2715553    T > C    i  No data  0.483  0.87  1.3  ILM 
  rs9303286g    G > C    i  0.06  0.093  0.617  0  Maldi 
  rs482284    G > A    i  0.283  0.267  1  0  Maldi 
  rs4890109    G > T    i  0.058  0.027  0.0016  2  ILM 
rxrα (Nr2b1; reTiNoid x reCePTor AlPhA) Chr9; Nm_002957
  rs3818740    T > C    i  0.225  0.294  0.423  4.7  ILM 
  rs3132297    C > T    i  0.222  0.157  1  0  Maldi 
  rs3118529    T > C    i  0.227  0.29  0.557  0  Maldi 
Table S1 | Continued
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  rs4240705    A > G    i  0.4  0.369  0.597  0.7  ILM 
  rs3118570    A > C    i  0.18  0.153  1  0  Maldi  Cauchi et al. (2003), 
                    Kölsch et al. (2009)
  rs1536475    G > A    i  0.17  0.163  1  0  Maldi  Kölsch et al. (2009)
  rs3132293    G > A    i  0.22  0.209  0.451  2.7  Maldi  Cauchi et al. (2003), 
                    Kölsch et al. (2009)
  rs1805348    G > A  A457  sc  0.025  0.023  1  0  Maldi 
SrC-1 (NCoA1; NuCleAr reCePTor CoACTiVATor 1) Chr2; Nm_003734
  rs995647    A > G    i  0.1  0.111  0.082  0.7  ILM 
  rs11677500    G > A    i  0.433  0.469  1  3.3  ILM 
  rs2119115    A > C    i  0.267  0.299  0.439  2  ILM 
  rs12468225    A > C    i  0.136  0.137  0.481  0  Maldi 
  rs4578807    A > G    i  0.133  0.145  0.512  1.3  ILM 
  rs4665716    A > G    i  0.075  0.055  0.007  2.7  ILM 
  rs11682130    T > G    i  0.433  0.473  0.514  1.3  ILM 
  rs6743362    A > C    i  0.058  0.034  0.205  0.7  ILM 
  rs12617941    G > A    i  0.075  0.047  0.274  0.7  ILM 
  rs6724282    A > G    3′  0.075  0.062  0.014  2.7  ILM 
  rs9309308    T > C    3′  0.225  0.297  0.242  1.3  ILM 
uSF1 (uPSTreAm STimulATorY FACTor 1) Chr1; Nm_009053
  rs3813609    C > G    5′c  0.3  0.373  0.601  0  Maldi  Holzapfel et al. (2008)
  rs2774279    G > A  R873  5′c  0.38  0.26  0.286  0  Maldi  Auro et al. (2008) 
       (ARHG 
        AP30)
  rs1556259    T > C    i  0.083  0.127  0.47  0  Maldi  Holzapfel et al. (2008)
  rs2774276    C > G    i  0.21  0.247  0.269  0  Maldi 
  rs2073658h    G > A    i  0.283  0.363  0.48  0  Maldi  OMIM, Meex et al. (2008)
  rs3737787h    C > T    3′u  0.309  0.363  0.48  0  Maldi  Holzapfel et al. (2008), 
                    Collings et al. (2008), 
                    Meex et al. (2008), 
                    Naukkarinen et al. (2005)
Vdr (Nr1i1; ViTAmiN d reCePTor) Chr12; Nm_000376
  rs4516035    T > C    5′  0.458  0.493  1  1.3  ILM 
  rs3890733    C > T    i  0.35  0.382  0.605  1.3  ILM 
  rs4760648    C > T    i  0.457  0.433  0.183  0.7  ILM 
  rs2853564    T > C    i  0.452  0.419  0.502  1.3  ILM 
  rs10735810    T > A  M1T  nc  0.442  0.34  0.71  4  Maldi  Guo et al. (2006), 
  (has merged 
  to rs2228570)
  rs11574090    C > G  L230V  nc  No data  0    0.7  Maldi 
  rs2239186    T > C    i  0.203  0.229  0.638  2.7  ILM 
  rs2189480    C > A    i  0.398  0.413  0.731  4  ILM 
  rs2239179    A > G    i  0.408  0.405  0.497  1.3  ILM 
  rs1540339    G > A    i  0.398  0.391  0.165  2  ILM 
  rs7962898    T > C    i  0.425  0.497  0.87  0  Maldi 
  rs1544410    G > A    i  0.442  0.4  0.609  0  Maldi  Purdue et al. (2007)
  rs7975232    A > C    i  0.422  0.493  1  0  Maldi  Purdue et al. (2007)
  rs731236    T > C  I352  sc  0.44  0.372  1  8.7  Maldi  Purdue et al. (2007)
i, Intronic; nc, non-synonymous coding; sc, synonymous coding; 3′u, 3′ untranslated region; 5′ upstream of mRNA; p, promoter; 3′, downstream of mRNA; Maldi, 
MALDI-TOF MS (mass assisted light desorption time of flight mass spectrometry) multiplexed genotyping assay; ILM, Illumina 300k Bead Chip; Tq-AD, TaqMan allelic 
discrimination genotyping assay (Applied Biosystems); calculation of MAF , minor allele frequency; HWp, Hardy–Weinberg p-value and missing values see Materials 
and Methods section.
aHapMapCEU or alternative population of Caucasian origin (dbSNP-homepage; Build 131).
bMinor allele frequency found in this study. 
cOverlap to ARHGAP30 coding region.
dLocated in CDC6 (cn).
e,f,g,h,iSNPs linked pairwise 100% within the one gene.
*MALDI-TOF genotype data provided by E. Schaeffeler, IKP , Stuttgart
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